We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Pharnext | EU:ALPHA | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0062 | -4.92% | 0.1198 | 0.107 | 0.12 | 0.157 | 0.101 | 0.137 | 427,963 | 16:40:00 |
Regulatory News:
Pharnext SA (FR0011191287 - ALPHA)(Paris:ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that senior management will be attending the following conferences taking place in November 2017 throughout Europe.
If you are interested in meeting the Pharnext management team during either of these events or if you need more information about Pharnext's participation, please send an email to investors@pharnext.com.
About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).For more information, visit www.pharnext.com.
1 https://ebdgroup.knect365.com/bioeurope/about-bio-europe2 http://www.jefferies.com/OurFirm/Conferences/325/3523 http://www.actionaria.com/4 http://www.midcapevents.com/geneva2017/home/
View source version on businesswire.com: http://www.businesswire.com/news/home/20171102005049/en/
PharnextXavier Paoli, +33 (0)1-4109-2230VP, Chief Commercial Officercontact@pharnext.comorInvestor Relations (Europe)MC Services AGAnne Hennecke, +49 211 529252 22anne.hennecke@mc-services.euorInvestor Relations (U.S.)Stern Investor Relations, Inc.Matthew Shinseki, +1-212-362-1200matthew@sternir.comorFinancial Communication (France)ActifinStéphane Ruiz, +33 (0)1-5688-1115sruiz@actifin.frorMedia Relations (Europe)ALIZE RPCaroline CarmagnolAurore Gangloffpharnext@alizerp.com+33 (0)1-4454-3664orMedia Relations (U.S.)RooneyPartnersMarion Janic, +1-212-223-4017mjanic@rooneyco.com
1 Year Pharnext Chart |
1 Month Pharnext Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions